Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis
M Tjepkema, S Amini, M Schipperus - Critical Reviews in Oncology …, 2022 - Elsevier
One possible side effect of thrombopoietin receptor agonists in immune thrombocytopenia is
thrombosis. Our aim is to systematically review whether patients with ITP that were treated …
thrombosis. Our aim is to systematically review whether patients with ITP that were treated …
Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a …
The thrombopoietin receptor agonist romiplostim is approved for second‐line use in chronic
immune thrombocytopenia (ITP), but its effects in patients with ITP for≤ 1 year are not well …
immune thrombocytopenia (ITP), but its effects in patients with ITP for≤ 1 year are not well …
Update on diagnosis and treatment of immune thrombocytopenia
Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …
[HTML][HTML] Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist …
DB Cines, T Gernsheimer, J Wasser, B Godeau… - International journal of …, 2015 - Springer
A safety analysis of pooled data from clinical studies of romiplostim, a thrombopoietin (TPO)
receptor agonist, in which patients with immune thrombocytopaenia (ITP) received …
receptor agonist, in which patients with immune thrombocytopaenia (ITP) received …
[HTML][HTML] Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of …
J Deng, H Hu, F Huang, C Huang, Q Huang… - Frontiers in …, 2021 - frontiersin.org
Thrombopoietin receptor agonists (TPO-RAs) play a crucial role in stimulating
thrombopoiesis. However, conventional meta-analyses have shown inconsistent results …
thrombopoiesis. However, conventional meta-analyses have shown inconsistent results …
Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
F Rodeghiero, R Stasi, A Giagounidis… - European journal of …, 2013 - Wiley Online Library
Background and objectives Thrombopoietin receptor agonists (TPO ra) are the only
treatments for immune thrombocytopenia (ITP) for which evidence of efficacy and safety from …
treatments for immune thrombocytopenia (ITP) for which evidence of efficacy and safety from …
[HTML][HTML] Management of immune thrombocytopenia: 2022 update of Korean experts recommendations
YH Park, DY Kim, S Kim, YB Choi, DY Shin… - Blood …, 2022 - ncbi.nlm.nih.gov
Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP),
there is currently little data from randomized trials to assist clinicians in managing patients …
there is currently little data from randomized trials to assist clinicians in managing patients …
Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review
Previous meta-analyses reported discordant results on the efficacy and safety of
thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with …
thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with …
[HTML][HTML] Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision
H Kashiwagi, M Kuwana, T Hato, T Takafuta… - International Journal of …, 2020 - Springer
In 2012, ITP group of Blood Coagulation Abnormalities Research Team with funding from
the Ministry of Health, Labour and Welfare Research Grant for Overcoming Intractable …
the Ministry of Health, Labour and Welfare Research Grant for Overcoming Intractable …
Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 study
C Neunert, J Despotovic, K Haley… - Pediatric blood & …, 2016 - Wiley Online Library
Background Data on second‐line treatment options for pediatric patients with immune
thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists (TPO‐RA) provide a …
thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists (TPO‐RA) provide a …